Dean Petkanas

Dean Petkanas

Company: Kannalife

Job title: Chief Executive Officer

Bio:

Mr. Petkanas is a corporate finance and executive management professional with over 25 years of investment banking and capital markets experience. 

In 2010 Mr. Petkanas co-founded Kannalife Sciences, Inc. and for the past 10 years was principally responsible for raising financing as well as the creation and execution of the Company’s business model, including the exclusive licensing of U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” from the National Institutes of Health. 

Mr. Petkanas is a co-inventor of 7 globally issued patents based on PCT Patent PCT/US2015/010827, WO2015/106108A2 titled“Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy”. The patents cover a family of proprietary monotherapeutic molecules focused on treating pain, neurodegeneration and oxidative stress-related diseases lead by KLS-13019, a potent, non-opioid alternative. The patent estate includesU.S. Patent 9,611,213U.S. Patent 10,004,722Japanese Patent JP6486950B2Russian Patent RU2676475C2Chinese Patent CN106456573B,  European Patent EP3094318B1, and Australian Patent AU2015204609B2. 

Mr. Petkanas is also co-author of the published articles: ACS Medicinal Chemistry Letters (2016, 7, 424-428)“Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability” and Journal of Molecular Neuroscience (14 August 2018)“Pharmacological Comparisons Between Cannabidiol and KLS-13019.” 

Seminars:

Live Presenter Q&A 12:40 pm

Read more

day: Day Two

Panel Discussion: Designing an IP Strategy from the Ground Up that Will Give you the Edge 12:50 pm

Download The Full Event Guide Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.